Literature DB >> 10477429

TP53 mutation and haplotype analysis of two large African American families.

J Hung1, B Mims, G Lozano, L Strong, C Harvey, T T Chen, V Stastny, G Tomlinson.   

Abstract

Two large apparently unrelated African American families with a high incidence of breast cancer and other tumors characteristic of Li-Fraumeni breast sarcoma cancer family syndrome were studied. Mutation screening revealed that in both families the affected members carried a germline mutation of the TP53 gene at codon 133 (ATG--> ACG, M133T). In order to determine whether an ancestral haplotype was shared by these two families, polymorphic markers within and flanking the TP53 gene were studied. Haplotype analysis using five markers revealed an identical haplotype shared by the two families. Loss of heterozygosity at the TP53 locus in the probands' tumor tissues from each family was observed; in each case, the retained allele carried the common haplotype. The frequency of this haplotype in the general African American population is <0.003. This unique haplotype, combined with the rare TP53 mutation, suggests that these African American families share a common ancestry. This finding suggests that other African Americans may be carriers of this mutation and thus may be at risk of early-onset breast cancer or other cancers characteristic of the Li-Fraumeni breast sarcoma cancer family syndrome. The finding of recurring mutations in African Americans may facilitate carrier screening and identification in this population. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  1999        PMID: 10477429     DOI: 10.1002/(SICI)1098-1004(1999)14:3<216::AID-HUMU4>3.0.CO;2-X

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  2 in total

1.  The first two confirmed sub-Saharan African families with germline TP53 mutations causing Li-Fraumeni syndrome.

Authors:  Shelley Macaulay; Quintin Clive Goodyear; Mia Kruger; Wenlong Chen; Fahmida Essop; Amanda Krause
Journal:  Fam Cancer       Date:  2018-10       Impact factor: 2.375

2.  Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients.

Authors:  Daphne S C Lee; Sook-Yee Yoon; Lai Meng Looi; Peter Kang; In Nee Kang; Kavitta Sivanandan; Hany Ariffin; Meow Keong Thong; Kin Fah Chin; Nur Aishah Mohd Taib; Cheng-Har Yip; Soo-Hwang Teo
Journal:  Breast Cancer Res       Date:  2012-04-16       Impact factor: 6.466

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.